Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.Annals of Hematology|October 29, 2013
Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IVLida Kalmanti, Susanne Saussele, Michael Lauseker, et al.Annals of Hematology|August 17, 2023
Step-in dosing of bosutinib in pts with chronic phase chronic myeloid leukemia (CML) after second-generation tyrosine kinase inhibitor (TKI) therapy: results of the Bosutinib Dose Optimization (BODO) StudySusanne Isfort, Kirsi Manz, Lino L Teichmann, et al.Cancers|August 27, 2021
Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN BioregistryJudith Gecht, Ioannis Tsoukakis, Kim Kricheldorf, et al.Haematologica|May 20, 2014
Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinibBenjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2013
Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IVRüdiger Hehlmann, Martin C Müller, Michael Lauseker, et al.Blood|November 1, 2011
Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVAlice Fabarius, Armin Leitner, Andreas Hochhaus, et al.Blood Advances|September 30, 2024
Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurinFrank G Rücker, Lars Bullinger, Sibylle Cocciardi, et al.Annals of Hematology|September 20, 2015
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CMLAlice Fabarius, Lida Kalmanti, Christian T Dietz, et al.Nature Communications|April 8, 2015
Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasmsWilliam Tapper, Amy V Jones, Robert Kralovics, et al.Pageof 4